CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Bookmark and Share
Published: 17 Jun 2020
Views: 572
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.

Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.